The latest price target for Anika Therapeutics (NASDAQ:ANIK) was reported by Barrington Research on November 1, 2024. The analyst firm set a price target for $25.00 expecting ANIK to rise to within 12 months (a possible 45.52% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Anika Therapeutics (NASDAQ:ANIK) was provided by Barrington Research, and Anika Therapeutics maintained their outperform rating.

The last upgrade for Anika Therapeutics Inc happened on August 14, 2023 when Barrington Research raised their price target to $24. Barrington Research previously had a market perform for Anika Therapeutics Inc.

The last downgrade for Anika Therapeutics Inc happened on March 7, 2023 when Barrington Research changed their price target from N/A to N/A for Anika Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anika Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anika Therapeutics was filed on November 1, 2024 so you should expect the next rating to be made available sometime around November 1, 2025.

While ratings are subjective and will change, the latest Anika Therapeutics (ANIK) rating was a maintained with a price target of $37.00 to $25.00. The current price Anika Therapeutics (ANIK) is trading at is $17.18, which is out of the analyst’s predicted range.